Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on October 26, 2021. The report details top-line results from the Phase 2/3 GAIN Trial evaluating atuzaginstat (COR388), an investigational oral small-molecule targeting gingipain proteases from Porphyromonas gingivalis for the treatment of mild to moderate Alzheimer's disease.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. No data regarding revenue, profit, cash flow, margins, debt, or liquidity is provided in this document.
Material Changes and Clinical Results
- Overall Cohort: The study of 643 participants did not meet statistical significance in co-primary cognitive (ADAS-Cog11) and functional (ADCS-ADL) endpoints.
- PG-DS Subgroup: In the pre-specified subgroup with detectable P. gingivalis DNA in saliva (n=242), a dose response was observed:
- 80 mg BID arm: 57% slowing of cognitive decline (p=0.02).
- 40 mg BID arm: 42% slowing of cognitive decline (p=0.07).
- Functional Endpoints: Significant benefits were not observed on the ADCS-ADL endpoint in the PG-DS subgroup.
- Correlations: Reductions in P. gingivalis in saliva correlated significantly with improved outcomes on ADAS-Cog11, CDR-SB, and MMSE.
- Periodontal Sub-study: Demonstrated a trend to benefit on pocket depth in the PG-DS subgroup.
Outlook, Risks, and Safety Profile
Management Commentary and Next Steps: The Company is engaging with regulators and stakeholders to advance atuzaginstat and its second-generation inhibitor, COR588 (once-daily administration). Further results will be presented at future scientific conferences.
Safety and Adverse Events:
- Gastrointestinal: Diarrhea (up to 16%) and nausea (6%) were more common in treated groups vs. placebo.
- Liver Enzymes: Dose-related elevations >3X upper limit of normal occurred in 7% (40 mg BID) and 15% (80 mg BID) of participants. Most were asymptomatic and resolved.
- Bilirubin: Two participants in the 80 mg BID arm had concomitant bilirubin elevations without alternative explanation.
- Imaging: No increase in ARIA (amyloid-related imaging abnormalities), microhemorrhage, edema, or superficial siderosis was observed.
Risks: Forward-looking statements are subject to uncertainties regarding clinical trial success, regulatory approvals, and the potential therapeutic benefits of the product candidates.
Investor Verification Checklist
- Verify the registrant name is Cortexyme, Inc. (CRTX), not Quince Therapeutics.
- Confirm the distinction between the overall cohort failure and the positive signal in the P. gingivalis-positive subgroup.
- Review the safety data regarding liver enzyme elevations and the two cases of concomitant bilirubin elevation.
- Monitor upcoming presentations for detailed data on the periodontal sub-study and the development timeline for COR588.
- Check subsequent filings for regulatory feedback following the Company's engagement with stakeholders.